Dermatology

A study found the Skin Barrier Meter accurately measures skin barrier function in children with atopic dermatitis, offering a fast, non-invasive assessment within 5 seconds.

Fifteen of 16 patients with chronic ulcers in a small study had positive patch test to common wound care products.

This interview highlights the significance of Bruckner’s recent phase 3 data on birch triterpenes as a potential treatment for dystrophic and junctional EB, as well as patients’ unmet needs.

Bruckner discusses her team’s long-term data on the safety and efficacy of birch bark extract, also known as Oleogel-S10, for those with epidermolysis bullosa.

A study found distinct DNA methylation patterns at birth linked to early-onset atopic dermatitis by age 2. Findings will be presented at AAAAI 2025.

These findings were from a 52-week analysis of a Phase-2 trial in participants with chronic spontaneous urticaria.

In these new findings, investigators highlight phase 1 research into ritlecitinib for patients aged 6 to 12 years with alopecia areata.

New 2-year data from the BE HEARD program shed further light on the role bimekizumab in treatment algorithms for HS.

Avapritinib 25mg daily significantly improved quality of life (QoL), disease control, and basal serum tryptase (BST) levels.

These data point to inaccessibility, distance from providers, and insurance-related barriers as obstacles to mental health improvement among children with atopic dermatitis.

A pooled analysis of LIBERTY-CSU CUPID Study A and Study C showed dupilumab reduces itch in patients with chronic spontaneous urticaria by week 24.

In this retrospective analysis, investigators in Japan highlighted the prevalence and incidence of comorbidities in those with atopic dermatitis, psoriasis, alopecia areata, and vitiligo.

The drug given this designation, known as rezpegaldesleukin, is indicated for adult and pediatric patients aged 12 years and older with atopic dermatitis.

This announcement by INmune Bio, Inc., follows positive findings in the MissionEB clinical trial evaluating CORDStrom for treatment of recessive dystrophic epidermolysis bullosa.

In this study, investigators highlighted factors associated with active hidradenitis suppurativa over the age of 50 such as smoking, male gender, and later onset of disease.

In this analysis, investigators conclude that health-related quality of life and clinical burdens are greater among patients with hidradenitis suppurativa and draining tunnels.

These data suggest that dupilumab’s drug survival rate at 12 and 24 months is greater than that of upadacitinib and tralokinumab among patients with atopic dermatitis.

In this analysis, investigators concluded that dupilumab may be a viable treatment choice for pregnant or breastfeeding mothers with atopic dermatitis.

These data point to milestone event frequency and prevalence by subtype of RDEB, highlighting such events as dysphagia and squamous cell carcinoma.

Adelaide Hebert, MD, discusses the impact of the recent approval for tapinarof cream in the management of atopic dermatitis.

Targeted anti-inflammatory treatment may be reasonable for addressing the causes ofsystemic inflammation in those with severe junctional and dystrophic epidermolysis bullosa.

In this episode, Nada Elbuluk, MD, and Michelle Rodrigues, MBBS, discuss diagnosis and management of pigmentary disorders in skin of color.

This review of January 2025 in dermatology news highlights new developments in the treatment of conditions such as psoriasis, alopecia areata, and atopic dermatitis.

This literature review explored the topic of hidradenitis suppurativa management during pregnancy and lactation, highlighting data available on this topic.

These findings highlight dupilumab’s use as a potential treatment option for individuals with prurigo nodularis.